tiprankstipranks
MAIA Biotechnology Advances with Clinical Trials and Partnerships
Company Announcements

MAIA Biotechnology Advances with Clinical Trials and Partnerships

Don't Miss Our Christmas Offers:

MAIA Biotechnology, Inc. ( (MAIA) ) has shared an announcement.

MAIA Biotechnology, Inc. is actively engaging with the financial community, presenting at the H.C. Wainwright Global Investment Conference and sharing updates on its website about their business and clinical progress, including a partnership with Regeneron. The company also announced promising survival data from a Phase 2 study of their cancer treatment, THIO, in Non-Small Cell Lung Cancer. However, investors are cautioned to consider the forward-looking nature of these statements, which are based on current management expectations and subject to risks and uncertainties that could cause actual results to differ.

See more data about MAIA stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyMAIA Biotechnology granted FDA rare pediatric disease designation for THIO
TheFlyMAIA Biotechnology to sell 507,364 shares at $1.872 in private placement
TheFlyMAIA Biotechnology, Regeneron expand clinical supply agreement
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App